Abstract: The present invention relates to a nanoliposome comprising a liposome membrane containing esterified lecithin, and one or more physiologically active ingredients included in inner space of the liposome membrane; a method for preparing the same; and a composition for preventing or treating skin diseases, comprising the same. The nanoliposome according to the present invention has long-term stability and uniformity, and so can be used to prepare a composition for skin having excellent moisturizing and penetrating properties, such as cosmetics, medicament for treating skin diseases, or the like. In particular, the present composition for preventing or treating skin diseases comprises epidermal growth factor included in the nanoliposome, thereby showing an excellent effect of stimulating skin-penetration and good pharmaceutical stability.

Abstract: Disclosed herein are diagnostic markers CTHRC1, CANP and KIAA0101, which are overexpressed specifically in breast or colorectal cancer. A method for diagnosing the cancer by-detecting the markers, and a method for preventing or treating by inhibiting the expression and activity of the markers are also disclosed.

Abstract: The present invention relates to novel human thrombopoietin (hTPO) derivatives, and to process of preparation thereof. Particularly, sugar chains are introduced into native hTPO by substituting amino acids such as asparagine for amino acids at specific positions in native hTPO, preparing novel hTPO derivatives with high activities enhancing the platelet production in vivo. Therefore, the novel hTPO derivatives of this invention may be useful for the treatment of thrombocytopenia associated with anticancer therapy or the transplantation of bone marrow.

Abstract: The present invention relates to novel human thrombopoietin (hTPO) derivatives, and to process of preparation thereof. Particularly, sugar chains are introduced into native hTPO by substituting amino acids such as asparagine for amino acids at specific positions in native hTPO, preparing novel hTPO derivatives with high activities enhancing the platelet production in vivo. Therefore, the novel hTPO derivatives of this invention may be useful for the treatment of thrombocytopenia associated with anticancer therapy or the transplantation of bone marrow.

Abstract: The present invention relates to novel human thrombopoietin (; hTPO) derivatives, and to process of preparation thereof. Particularly, sugar chains are introduced into native hTPO by substituting amino acids such as asparagine for amino acids at specific positions in native hTPO, preparing novel hTPO derivatives with high activities enhancing the platelet production in vivo. Therefore, the novel hTPO derivatives of this invention may be useful for the treatment of thrombocytopenia associated with anticancer therapy or the transplantation of bone marrow.

Abstract: The present invention provides a genetically engineered fusion protein consisting of hEGF that is internalized inside of the cells after tracing down the cancer cells expressing hEGF receptors and human angiogenin that is cytotoxic by degrading ribonucleotide upon internalization, a process for preparing a fusion protein in a large quantity by transforming E. coli with the expression vectors containing the gene encoding the fusion protein, and pharmaceutical application of the fusion protein as an anticancer agent. All components of the fusion protein form no antibodies and exhibit no immunotoxicity since they are derived from human. Each component alone is inactive to the cancer cells, however, once they are fused together, they kill the cancer cells selectively with a difference of 1000 fold in IC50 in spite of its low molecular weight. Therefore, the fusion protein of the present invention is capable of treating the cancer expressing hEGF receptors at high level without showing toxicity.

Abstract: The present invention relates to a recombinant expression vector containing a fusion gene which is prepared by ligating adhesion gene of H. pylori and A2 and B subunit genes of Vibrio cholerae toxin, and a process for preparing a chimeric protein employing a recombinant microorganism transformed with the said expression vector. The recombinant DNA which is designed for convenient expression and gene manipulation, may express a chimeric protein having excellent immunogenicity to H. pylori, which is stable in stomach, and penetrate mucous membrane of stomach easily, finally to stimulate production of sIgA. Accordingly, the chimeric protein expressed from the recombinant DNA may be used as an active ingredient of the diagnostic kit for H. pylori infection and preventive or therapeutic vaccine for H. pylori-associated diseases, and may be used in the production of anti-H. pylori antibody.

Abstract: The present invention relates to a novel gene coding human epidermal growth factor("hEGF") and a process for preparing the same employing a recombinant expression vector therefor. The hEGF gene of the invention is designed to contain codons ubiquitous in E. coli and the following restriction sites: HpaI at the 5' terminal, PstI at the 3' terminal and Bpu1102I, NsiI, MluI, Eco47III and AflII at a regular manner within its internal sequence. The present invention also provides a process for preparing hEGF by employing a expression vector pTE105 for hEGF, which contains expression cassette comprising Omp A leader sequence, translation termination sequence and transcription termination sequence and hEGF gene; and, replication origin of pUC19, tetracycline-resistant marker and a par site for stabilization in E. coli. The hEGF is produced massively in E. coli transformed with the pTE105(KCCM 10027).